Andrew Allen, Gritstone Oncology on Cancer Neoantigen Vaccines

Описание к видео Andrew Allen, Gritstone Oncology on Cancer Neoantigen Vaccines

Neoantigens arise from somatic mutations that differ from normal cell antigens and are specific to each individual patient – providing tumor specific targets for developing personalized cancer vaccines. Current clinical trials using neoantigen targeting cancer vaccines, including in combination with checkpoint blockade monoclonal antibodies, have demonstrated potent T-cell responses against those neoantigens accompanied by tumor regression in patients. Personalized neoantigen vaccines represent one of the most significant advances in the history of cancer treatment.

Комментарии

Информация по комментариям в разработке

Похожие видео